Terra Australis Pharmaceuticals

Terra Australis Pharmaceuticals (TAP) is an Australian biopharmaceutical company specializing in the development and manufacture of medicinal cannabis products. The company was founded to capitalize on Australia's regulatory framework for botanical medicines, focusing on securing licenses for cultivation, research, and manufacturing. In 2018, TAP was acquired by Cann Group Limited in a strategic move to consolidate licensing assets and expand production capacity within the Australian market. The acquisition allowed Cann Group to integrate TAP's specialized knowledge in cannabinoid extraction and formulation. TAP's primary therapeutic focus involves using phytocannabinoids to treat conditions such as chronic pain, epilepsy, and multiple sclerosis. The company operates as a subsidiary, contributing to the broader pipeline of pharmaceutical-grade cannabis treatments.